Calcium Channel Blockers Compared to Magnesium Sulfate in Fetal Cerebral Blood Flow

• Status: Completed
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to investigate the possible use of calcium channel as a neuroprotectant in cases with PTL. This will be done by comparing the effect they have on cerebral blood vessels with the already established MgSo4. They have been proven superior to magnesium sulphate in tocolysis, and they possess the mechanism of action that would allow for their theoretical use as neuroprotective agents.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kasr El Aini Hospital
• Treatments: Calcium Channel Blockers; Calcium, Dietary; Magnesium Sulfate; Nifedipine

Criteria

• Inclusion Criteria:

• in imminent preterm labour ( , >4cm dilated, cervical effacement > 60%).

• < 32 weeks gestational age.

• Exclusion Criteria:

• patients will be excluded from the study if the gestational age was > 32 weeks

• intrauterine fetal death

• multiple gestation

• fetal malformations where only palliative care is needed

• placental abruption

• Chorioamnionitis

• pre-ecplamsia, or diabetes

• suspected fetal compromise diagnosed by ultrasound or CTG requiring delivery, -any indication for caesarean section

• fetal growth restriction

• Also any contraindication to the use of Nifedipine e.g maternal cardiac disease, allergy to Nifedipine, hypotension, or hepatic dysfunction

• Contraindications To MgSo4 use as Myasthenia Gravis, progressive muscle weakness ,allergy to MgSo4, severe renal impairment & heart block.